JP6968054B2 - Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 - Google Patents

Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 Download PDF

Info

Publication number
JP6968054B2
JP6968054B2 JP2018507527A JP2018507527A JP6968054B2 JP 6968054 B2 JP6968054 B2 JP 6968054B2 JP 2018507527 A JP2018507527 A JP 2018507527A JP 2018507527 A JP2018507527 A JP 2018507527A JP 6968054 B2 JP6968054 B2 JP 6968054B2
Authority
JP
Japan
Prior art keywords
pde3a
cancer
dnmdp
slfn12
modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018507527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531892A5 (enExample
JP2018531892A (ja
Inventor
リュック・デ・ワール
マシュー・メイヤーソン
ハイディ・グルーリック
モニカ・シェノン
アレックス・バーギン
シャオユン・ウ
ウルリケ・ザック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Broad Institute Inc
Original Assignee
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Institute Inc filed Critical Broad Institute Inc
Publication of JP2018531892A publication Critical patent/JP2018531892A/ja
Publication of JP2018531892A5 publication Critical patent/JP2018531892A5/ja
Priority to JP2021114249A priority Critical patent/JP2021169488A/ja
Application granted granted Critical
Publication of JP6968054B2 publication Critical patent/JP6968054B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2018507527A 2015-08-13 2016-08-12 Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 Active JP6968054B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021114249A JP2021169488A (ja) 2015-08-13 2021-07-09 Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562204875P 2015-08-13 2015-08-13
US62/204,875 2015-08-13
PCT/US2016/046912 WO2017027854A1 (en) 2015-08-13 2016-08-12 Compositions and methods for cancer expressing pde3a or slfn12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021114249A Division JP2021169488A (ja) 2015-08-13 2021-07-09 Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法

Publications (3)

Publication Number Publication Date
JP2018531892A JP2018531892A (ja) 2018-11-01
JP2018531892A5 JP2018531892A5 (enExample) 2019-09-26
JP6968054B2 true JP6968054B2 (ja) 2021-11-17

Family

ID=57983814

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018507527A Active JP6968054B2 (ja) 2015-08-13 2016-08-12 Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法
JP2021114249A Pending JP2021169488A (ja) 2015-08-13 2021-07-09 Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021114249A Pending JP2021169488A (ja) 2015-08-13 2021-07-09 Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法

Country Status (6)

Country Link
US (2) US11207320B2 (enExample)
EP (1) EP3334404B1 (enExample)
JP (2) JP6968054B2 (enExample)
CN (2) CN114699528A (enExample)
CA (1) CA2995375C (enExample)
WO (1) WO2017027854A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3411037B1 (en) 2016-02-05 2021-10-20 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
CN107312824A (zh) * 2016-04-26 2017-11-03 中国科学院上海药物研究所 Pde3a在判断阿那格雷治疗肿瘤效果中的应用
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
US12325880B2 (en) 2018-11-01 2025-06-10 The Broad Institute, Inc. Identification of PDE3 modulator responsive cancers
CA3128293A1 (en) 2019-02-01 2020-08-06 Bayer Aktiengesellschaft 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
CN112402613A (zh) * 2019-08-23 2021-02-26 中国科学院上海药物研究所 Pde3抑制剂与细胞因子联合治疗肿瘤的应用
CN117279644A (zh) * 2021-03-03 2023-12-22 拜耳股份有限公司 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮
CN117062819A (zh) * 2021-03-23 2023-11-14 北京生命科学研究所 多环化合物及其用途
CN114814221A (zh) * 2022-02-24 2022-07-29 中南大学湘雅医院 一种甲状腺癌早期诊断标志物及其应用
CN116705196B (zh) * 2023-06-28 2025-08-19 湖南师范大学 基于符号图神经网络的药物靶标互作用预测方法及装置

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052395A (en) 1975-09-11 1977-10-04 Sankyo Company Limited Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones
US4092311A (en) 1976-06-03 1978-05-30 American Cyanamid Company Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates
JPS6061570A (ja) 1983-09-16 1985-04-09 Sankyo Co Ltd ピリダジノン誘導体及び農業用殺菌剤
US5053338A (en) 1989-09-01 1991-10-01 Glaxo Inc. Kinetic resolution of pyridazinones using lipase
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
JPH05140116A (ja) 1991-11-21 1993-06-08 Nippon Soda Co Ltd 光学活性な化合物
US5856480A (en) 1994-11-11 1999-01-05 Nippon Soda Co., Ltd. Optically active compound
EP1406621A2 (en) * 2001-06-26 2004-04-14 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
CA2782620A1 (en) * 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
EP2739751A1 (en) 2011-08-03 2014-06-11 Signal Pharmaceuticals, LLC Identification of gene expression profile as a predictive biomarker for lkb1 status
US9890127B2 (en) * 2013-03-11 2018-02-13 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
CA2927708C (en) * 2013-10-17 2021-05-25 Sartar Therapeutics Ltd Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
JP5852759B1 (ja) * 2015-04-01 2016-02-03 株式会社キュービクス 遺伝子発現解析による膵臓癌の検出
EP3411037B1 (en) * 2016-02-05 2021-10-20 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
WO2018141835A1 (en) * 2017-02-03 2018-08-09 The Broad Institute, Inc. Compounds, compositions and methods for cancer treatment
US12325880B2 (en) * 2018-11-01 2025-06-10 The Broad Institute, Inc. Identification of PDE3 modulator responsive cancers

Also Published As

Publication number Publication date
EP3334404B1 (en) 2024-09-18
JP2021169488A (ja) 2021-10-28
CN114699528A (zh) 2022-07-05
US11207320B2 (en) 2021-12-28
CN108366947B (zh) 2022-03-29
CN108366947A (zh) 2018-08-03
CA2995375C (en) 2024-06-18
CA2995375A1 (en) 2017-02-16
JP2018531892A (ja) 2018-11-01
EP3334404A1 (en) 2018-06-20
WO2017027854A1 (en) 2017-02-16
EP3334404A4 (en) 2019-02-13
US20180235961A1 (en) 2018-08-23
US20220071995A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
JP6968054B2 (ja) Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法
CN108883112B (zh) 用于癌症患者分级和癌症治疗的化合物、组合物和方法
Guièze et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies
Brenke et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity
KR102511807B1 (ko) 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
JP2020511401A (ja) 癌の治療法のためのｂｒｄ４阻害剤と葉酸代謝拮抗薬との組み合わせ物
JP2019508496A (ja) 癌の治療法のためのｔａｆ１阻害剤
JP2021072776A (ja) Ｔｔｋ阻害剤化学療法の為の予後バイオマーカー
KR20190112767A (ko) 에스트로겐 수용체 조절인자
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
Qi et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas
US11786542B2 (en) Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways
Carbone et al. Novel Pyrazolo [1, 5‐a]− 1, 3, 5‐Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models
Riaño Canalias The effect of inhibition of nucleotide synthesis on ribosome biogenesis and the induction of p53

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210709

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210709

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210719

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211026

R150 Certificate of patent or registration of utility model

Ref document number: 6968054

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250